Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kai Song [verfasserIn] Xuan Jin [verfasserIn] Moo-Hyun Kim [verfasserIn] Jia-Xin Li [verfasserIn] Cai-De Jin [verfasserIn] Song-Lin Yuan [verfasserIn] Zhao-Yan Song [verfasserIn] En-Ze Jin [verfasserIn] Kwang-Min Lee [verfasserIn] Kyung-Hee Lim [verfasserIn] Young-Rak Cho [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Journal of Clinical Medicine - MDPI AG, 2013, 11(2022), 9, p 2480 |
|---|---|
| Übergeordnetes Werk: |
volume:11 ; year:2022 ; number:9, p 2480 |
| Links: |
|---|
| DOI / URN: |
10.3390/jcm11092480 |
|---|
| Katalog-ID: |
DOAJ042662508 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ042662508 | ||
| 003 | DE-627 | ||
| 005 | 20240414225059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11092480 |2 doi | |
| 035 | |a (DE-627)DOAJ042662508 | ||
| 035 | |a (DE-599)DOAJfc0c575581344e3ea42f2c7918a14793 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Kai Song |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy. | ||
| 650 | 4 | |a optimal platelet reactivity | |
| 650 | 4 | |a P2Y12 inhibitors | |
| 650 | 4 | |a VerifyNow | |
| 650 | 4 | |a multiple electrode aggregometry | |
| 650 | 4 | |a light transmittance aggregometry | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Xuan Jin |e verfasserin |4 aut | |
| 700 | 0 | |a Moo-Hyun Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Jia-Xin Li |e verfasserin |4 aut | |
| 700 | 0 | |a Cai-De Jin |e verfasserin |4 aut | |
| 700 | 0 | |a Song-Lin Yuan |e verfasserin |4 aut | |
| 700 | 0 | |a Zhao-Yan Song |e verfasserin |4 aut | |
| 700 | 0 | |a En-Ze Jin |e verfasserin |4 aut | |
| 700 | 0 | |a Kwang-Min Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Kyung-Hee Lim |e verfasserin |4 aut | |
| 700 | 0 | |a Young-Rak Cho |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 11(2022), 9, p 2480 |w (DE-627)718632478 |w (DE-600)2662592-1 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:9, p 2480 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm11092480 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/fc0c575581344e3ea42f2c7918a14793 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/11/9/2480 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 9, p 2480 | ||
| author_variant |
k s ks x j xj m h k mhk j x l jxl c d j cdj s l y sly z y s zys e z j ezj k m l kml k h l khl y r c yrc |
|---|---|
| matchkey_str |
article:20770383:2022----::ifrneiotmlltlteciiyfeptnpy2niiotetetnctcrnrsnrmptetudr |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.3390/jcm11092480 doi (DE-627)DOAJ042662508 (DE-599)DOAJfc0c575581344e3ea42f2c7918a14793 DE-627 ger DE-627 rakwb eng Kai Song verfasserin aut Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy. optimal platelet reactivity P2Y12 inhibitors VerifyNow multiple electrode aggregometry light transmittance aggregometry Medicine R Xuan Jin verfasserin aut Moo-Hyun Kim verfasserin aut Jia-Xin Li verfasserin aut Cai-De Jin verfasserin aut Song-Lin Yuan verfasserin aut Zhao-Yan Song verfasserin aut En-Ze Jin verfasserin aut Kwang-Min Lee verfasserin aut Kyung-Hee Lim verfasserin aut Young-Rak Cho verfasserin aut In Journal of Clinical Medicine MDPI AG, 2013 11(2022), 9, p 2480 (DE-627)718632478 (DE-600)2662592-1 20770383 nnns volume:11 year:2022 number:9, p 2480 https://doi.org/10.3390/jcm11092480 kostenfrei https://doaj.org/article/fc0c575581344e3ea42f2c7918a14793 kostenfrei https://www.mdpi.com/2077-0383/11/9/2480 kostenfrei https://doaj.org/toc/2077-0383 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2022 9, p 2480 |
| spelling |
10.3390/jcm11092480 doi (DE-627)DOAJ042662508 (DE-599)DOAJfc0c575581344e3ea42f2c7918a14793 DE-627 ger DE-627 rakwb eng Kai Song verfasserin aut Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy. optimal platelet reactivity P2Y12 inhibitors VerifyNow multiple electrode aggregometry light transmittance aggregometry Medicine R Xuan Jin verfasserin aut Moo-Hyun Kim verfasserin aut Jia-Xin Li verfasserin aut Cai-De Jin verfasserin aut Song-Lin Yuan verfasserin aut Zhao-Yan Song verfasserin aut En-Ze Jin verfasserin aut Kwang-Min Lee verfasserin aut Kyung-Hee Lim verfasserin aut Young-Rak Cho verfasserin aut In Journal of Clinical Medicine MDPI AG, 2013 11(2022), 9, p 2480 (DE-627)718632478 (DE-600)2662592-1 20770383 nnns volume:11 year:2022 number:9, p 2480 https://doi.org/10.3390/jcm11092480 kostenfrei https://doaj.org/article/fc0c575581344e3ea42f2c7918a14793 kostenfrei https://www.mdpi.com/2077-0383/11/9/2480 kostenfrei https://doaj.org/toc/2077-0383 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2022 9, p 2480 |
| allfields_unstemmed |
10.3390/jcm11092480 doi (DE-627)DOAJ042662508 (DE-599)DOAJfc0c575581344e3ea42f2c7918a14793 DE-627 ger DE-627 rakwb eng Kai Song verfasserin aut Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy. optimal platelet reactivity P2Y12 inhibitors VerifyNow multiple electrode aggregometry light transmittance aggregometry Medicine R Xuan Jin verfasserin aut Moo-Hyun Kim verfasserin aut Jia-Xin Li verfasserin aut Cai-De Jin verfasserin aut Song-Lin Yuan verfasserin aut Zhao-Yan Song verfasserin aut En-Ze Jin verfasserin aut Kwang-Min Lee verfasserin aut Kyung-Hee Lim verfasserin aut Young-Rak Cho verfasserin aut In Journal of Clinical Medicine MDPI AG, 2013 11(2022), 9, p 2480 (DE-627)718632478 (DE-600)2662592-1 20770383 nnns volume:11 year:2022 number:9, p 2480 https://doi.org/10.3390/jcm11092480 kostenfrei https://doaj.org/article/fc0c575581344e3ea42f2c7918a14793 kostenfrei https://www.mdpi.com/2077-0383/11/9/2480 kostenfrei https://doaj.org/toc/2077-0383 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2022 9, p 2480 |
| allfieldsGer |
10.3390/jcm11092480 doi (DE-627)DOAJ042662508 (DE-599)DOAJfc0c575581344e3ea42f2c7918a14793 DE-627 ger DE-627 rakwb eng Kai Song verfasserin aut Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy. optimal platelet reactivity P2Y12 inhibitors VerifyNow multiple electrode aggregometry light transmittance aggregometry Medicine R Xuan Jin verfasserin aut Moo-Hyun Kim verfasserin aut Jia-Xin Li verfasserin aut Cai-De Jin verfasserin aut Song-Lin Yuan verfasserin aut Zhao-Yan Song verfasserin aut En-Ze Jin verfasserin aut Kwang-Min Lee verfasserin aut Kyung-Hee Lim verfasserin aut Young-Rak Cho verfasserin aut In Journal of Clinical Medicine MDPI AG, 2013 11(2022), 9, p 2480 (DE-627)718632478 (DE-600)2662592-1 20770383 nnns volume:11 year:2022 number:9, p 2480 https://doi.org/10.3390/jcm11092480 kostenfrei https://doaj.org/article/fc0c575581344e3ea42f2c7918a14793 kostenfrei https://www.mdpi.com/2077-0383/11/9/2480 kostenfrei https://doaj.org/toc/2077-0383 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2022 9, p 2480 |
| allfieldsSound |
10.3390/jcm11092480 doi (DE-627)DOAJ042662508 (DE-599)DOAJfc0c575581344e3ea42f2c7918a14793 DE-627 ger DE-627 rakwb eng Kai Song verfasserin aut Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy. optimal platelet reactivity P2Y12 inhibitors VerifyNow multiple electrode aggregometry light transmittance aggregometry Medicine R Xuan Jin verfasserin aut Moo-Hyun Kim verfasserin aut Jia-Xin Li verfasserin aut Cai-De Jin verfasserin aut Song-Lin Yuan verfasserin aut Zhao-Yan Song verfasserin aut En-Ze Jin verfasserin aut Kwang-Min Lee verfasserin aut Kyung-Hee Lim verfasserin aut Young-Rak Cho verfasserin aut In Journal of Clinical Medicine MDPI AG, 2013 11(2022), 9, p 2480 (DE-627)718632478 (DE-600)2662592-1 20770383 nnns volume:11 year:2022 number:9, p 2480 https://doi.org/10.3390/jcm11092480 kostenfrei https://doaj.org/article/fc0c575581344e3ea42f2c7918a14793 kostenfrei https://www.mdpi.com/2077-0383/11/9/2480 kostenfrei https://doaj.org/toc/2077-0383 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2022 9, p 2480 |
| language |
English |
| source |
In Journal of Clinical Medicine 11(2022), 9, p 2480 volume:11 year:2022 number:9, p 2480 |
| sourceStr |
In Journal of Clinical Medicine 11(2022), 9, p 2480 volume:11 year:2022 number:9, p 2480 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
optimal platelet reactivity P2Y12 inhibitors VerifyNow multiple electrode aggregometry light transmittance aggregometry Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Journal of Clinical Medicine |
| authorswithroles_txt_mv |
Kai Song @@aut@@ Xuan Jin @@aut@@ Moo-Hyun Kim @@aut@@ Jia-Xin Li @@aut@@ Cai-De Jin @@aut@@ Song-Lin Yuan @@aut@@ Zhao-Yan Song @@aut@@ En-Ze Jin @@aut@@ Kwang-Min Lee @@aut@@ Kyung-Hee Lim @@aut@@ Young-Rak Cho @@aut@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
718632478 |
| id |
DOAJ042662508 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ042662508</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414225059.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/jcm11092480</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ042662508</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJfc0c575581344e3ea42f2c7918a14793</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Kai Song</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">optimal platelet reactivity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">P2Y12 inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">VerifyNow</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multiple electrode aggregometry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">light transmittance aggregometry</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xuan Jin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Moo-Hyun Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jia-Xin Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cai-De Jin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Song-Lin Yuan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhao-Yan Song</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">En-Ze Jin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kwang-Min Lee</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kyung-Hee Lim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Young-Rak Cho</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Clinical Medicine</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">11(2022), 9, p 2480</subfield><subfield code="w">(DE-627)718632478</subfield><subfield code="w">(DE-600)2662592-1</subfield><subfield code="x">20770383</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:9, p 2480</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/jcm11092480</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/fc0c575581344e3ea42f2c7918a14793</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2077-0383/11/9/2480</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2077-0383</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2022</subfield><subfield code="e">9, p 2480</subfield></datafield></record></collection>
|
| author |
Kai Song |
| spellingShingle |
Kai Song misc optimal platelet reactivity misc P2Y12 inhibitors misc VerifyNow misc multiple electrode aggregometry misc light transmittance aggregometry misc Medicine misc R Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention |
| authorStr |
Kai Song |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)718632478 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
20770383 |
| topic_title |
Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention optimal platelet reactivity P2Y12 inhibitors VerifyNow multiple electrode aggregometry light transmittance aggregometry |
| topic |
misc optimal platelet reactivity misc P2Y12 inhibitors misc VerifyNow misc multiple electrode aggregometry misc light transmittance aggregometry misc Medicine misc R |
| topic_unstemmed |
misc optimal platelet reactivity misc P2Y12 inhibitors misc VerifyNow misc multiple electrode aggregometry misc light transmittance aggregometry misc Medicine misc R |
| topic_browse |
misc optimal platelet reactivity misc P2Y12 inhibitors misc VerifyNow misc multiple electrode aggregometry misc light transmittance aggregometry misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of Clinical Medicine |
| hierarchy_parent_id |
718632478 |
| hierarchy_top_title |
Journal of Clinical Medicine |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)718632478 (DE-600)2662592-1 |
| title |
Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention |
| ctrlnum |
(DE-627)DOAJ042662508 (DE-599)DOAJfc0c575581344e3ea42f2c7918a14793 |
| title_full |
Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention |
| author_sort |
Kai Song |
| journal |
Journal of Clinical Medicine |
| journalStr |
Journal of Clinical Medicine |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| author_browse |
Kai Song Xuan Jin Moo-Hyun Kim Jia-Xin Li Cai-De Jin Song-Lin Yuan Zhao-Yan Song En-Ze Jin Kwang-Min Lee Kyung-Hee Lim Young-Rak Cho |
| container_volume |
11 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kai Song |
| doi_str_mv |
10.3390/jcm11092480 |
| author2-role |
verfasserin |
| title_sort |
differences in optimal platelet reactivity after potent p2y12 inhibitor treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention |
| title_auth |
Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention |
| abstract |
Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy. |
| abstractGer |
Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy. |
| abstract_unstemmed |
Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
9, p 2480 |
| title_short |
Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention |
| url |
https://doi.org/10.3390/jcm11092480 https://doaj.org/article/fc0c575581344e3ea42f2c7918a14793 https://www.mdpi.com/2077-0383/11/9/2480 https://doaj.org/toc/2077-0383 |
| remote_bool |
true |
| author2 |
Xuan Jin Moo-Hyun Kim Jia-Xin Li Cai-De Jin Song-Lin Yuan Zhao-Yan Song En-Ze Jin Kwang-Min Lee Kyung-Hee Lim Young-Rak Cho |
| author2Str |
Xuan Jin Moo-Hyun Kim Jia-Xin Li Cai-De Jin Song-Lin Yuan Zhao-Yan Song En-Ze Jin Kwang-Min Lee Kyung-Hee Lim Young-Rak Cho |
| ppnlink |
718632478 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.3390/jcm11092480 |
| up_date |
2024-07-03T13:20:37.087Z |
| _version_ |
1803564180666580992 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ042662508</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414225059.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/jcm11092480</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ042662508</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJfc0c575581344e3ea42f2c7918a14793</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Kai Song</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: East Asian patients receiving treatment with the potent P<sub<2</sub<Y<sub<12</sub< inhibitors prasugrel or ticagrelor experience more potent platelet inhibition than with clopidogrel. Methods: This study investigated differences in OPR rates with reduced doses of prasugrel (<i<n</i< = 38) or ticagrelor (<i<n</i< = 40) for maintenance therapy in 118 Korean ACS patients who had undergone PCI, in comparison to conventional-dose clopidogrel (<i<n</i< = 40). We assessed drug responses at one- and three-months post-PCI with VerifyNow and multiple electrode aggregometry assays. Results: At the one-month period, patients receiving standard-dose prasugrel or ticagrelor had lower platelet reactivity as determined by the three assays than those receiving the conventional dose of clopidogrel (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.000; LTA: <i<p</i< = 0.000). At the 3-month point, platelet reactivity was lower in those receiving reduced-dose prasugrel or ticagrelor than the clopidogrel-treated patients (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.012; LTA: <i<p</i< = 0.002). Prasugrel resulted in significantly lower platelet inhibition than ticagrelor as determined by VN and LTA (VN: <i<p</i< = 0.000; LTA: <i<p</i< = 0.003). At three months, there was a significant overall difference in OPR among the three groups when measured by VN (<i<p</i< < 0.001), but not when measured by MEA (<i<p</i< = 0.596). OPR in the reduced-dose prasugrel group was not significantly different to the clopidogrel group at three months (VN: <i<p</i< = 0.180; MEA: <i<p</i< = 0.711). OPR in the reduced-dose ticagrelor group was similar to clopidogrel as determined by MEA at three months, but was different when assessed by VN (VN: <i<p</i< = 0.000; MEA: <i<p</i< = 0.540). Compared to standard-dose, the reduced-dose prasugrel OPR rate was significantly increased (VN: <i<p</i< = 0.008; MEA: <i<p</i< = 0.020). Conclusions: OPR values for reduced-dose prasugrel and conventional-dose clopidogrel at three months were similar but higher than for reduced-dose ticagrelor as determined by VN, but no differences were noted by MEA. The MEA assay might have less sensitivity and consistency than the VN assay. Further studies are needed to explore this discrepancy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">optimal platelet reactivity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">P2Y12 inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">VerifyNow</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multiple electrode aggregometry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">light transmittance aggregometry</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xuan Jin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Moo-Hyun Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jia-Xin Li</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cai-De Jin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Song-Lin Yuan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhao-Yan Song</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">En-Ze Jin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kwang-Min Lee</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kyung-Hee Lim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Young-Rak Cho</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Clinical Medicine</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">11(2022), 9, p 2480</subfield><subfield code="w">(DE-627)718632478</subfield><subfield code="w">(DE-600)2662592-1</subfield><subfield code="x">20770383</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:9, p 2480</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/jcm11092480</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/fc0c575581344e3ea42f2c7918a14793</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2077-0383/11/9/2480</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2077-0383</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2022</subfield><subfield code="e">9, p 2480</subfield></datafield></record></collection>
|
| score |
7.400428 |